AKA. V. Knyazev

A. V. Knyazev

*This is an algorithmically generated author record based on publicly available information.

A. V. Knyazev has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of the efficacy and safety of botulinum toxin type A injections for the prevention of aspiration complications in patients with neurogenic dysphagia and posterior sialorrhea of various etiologies

    by S.E. Khatkova, O.A. Pogoreltseva, A.P. Kilina, A.V. Knyazev

    Objective. To evaluate the efficacy and safety of incobotulinumtoxinA injections into the salivary glands for preventing aspiration complications in patients with neurogenic dysphagia and posterior sialorrhea of various etiologies. Material and methods. A prospective study conducted in 2024—2025 included 116 patients divided into two groups. The Main group (n=58) received ultrasound-guided chemodenervation of four salivary glands (two parotid and two submandibular) with incobotulinumtoxinA, total dose 100 U. The Control group (n=58) consisted of retrospective data from patients with similar profiles who did not receive botulinum toxin injections. All patients underwent a comprehensive diagnostic workup, including neurological assessment, instrumental methods (flexible endoscopic evaluation of swallowing, chest CT scan), and non-instrumental scales for dysphagia and cognitive function. To objectify the severity of posterior sialorrhea, the authors developed and applied a Posterior Sialorrhea Intensity Visual Scale (PSIVS). Efficacy was assessed based on the dynamics of sialorrhea intensity, changes in feeding route, the incidence of aspiration pneumonia, and the timing of tracheostomy tube decannulation. Results. In the main group, by day 28 post-injection, the vast majority of patients (54 out of 58) showed a significant reduction in sialorrhea intensity to 0—1 points on the PSIVS (compared to 2—3 points initially). Following the reduction in sialorrhea and rehabilitation, 51 patients improved their feeding route (transitioning from tube/gastrostomy to oral or combined feeding) and decannulation was successfully performed in 14 patients. Three cases of aspiration pneumonia (5.2%) were recorded in the main group, compared to 12 cases (20.7%) in the control group. No serious adverse events were reported. Two patients experienced mild dry mouth, which resolved within one month. Conclusion. Incorporating salivary gland chemodenervation with incobotulinumtoxinA (100 U) into the diagnostic and treatment algorithm for neurogenic dysphagia and posterior sialorrhea is an effective and safe method for preventing aspiration complications. This technique significantly reduces sialorrhea intensity and the incidence of aspiration pneumonia, improves swallowing function, facilitates patient care, and enhances the rehabilitation prognosis for severe neurological patients, starting from the acute disease phase. Implementing this method into the routine practice of rehabilitation facilities is advisable to reduce mortality, disability, and the financial burden on the healthcare system.

  • Combined management of spasticity and sialorrhea in children with cerebral palsy: a Russian multicenter retrospective study

    by A. L. Kurenkov, D. A. Krasavina, E. A. Moroshek, T. A. Belogorova, V. V. Chernikov, A. R. Artemenko, A. V. Knyazev, M. M. Geraskina, B. I. Bursagova, L. M. Kuzenkova, et al.

    The use of botulinum toxin therapy to correct spasticity and sialorrhea in a single injection session is an adequate treatment strategy for children with cerebral palsy (CP), as these two conditions are often observed simultaneously in patients and negatively affect the course of the disease and quality of life. Objective: to evaluate the efficacy and safety of simultaneous correction of spasticity and sialorrhea with incobotulinumtoxin A in patients with CP. Material and methods . A retrospective analysis was conducted of the medical records of pediatric patients with spastic forms of CP with varying levels of motor ability (from level I to level V according to the Gross Motor Function Classification System, GMFCS) who had spasticity and sialorrhea of varying severity. The analysis included only those patients who underwent simultaneous correction of spasticity and sialorrhea with incobotulinumtoxin A during a single injection session. The total average dose for the correction of spasticity of the upper limbs (UL) and lower limbs (LL), the average dose for the correction of sialorrhea, the total average and maximum dose of the drug per injection session, the dynamics on the modified Ashworth scale (MAS) and the Drooling Impact Scale (DIS), as well as the overall improvement in sialorrhea on the Global Impression of Change Scale (GICS) during treatment were assessed. The severity of the therapeutic effect of the drug after repeated injections was studied, and an analysis of adverse events (AEs) was performed throughout all injection cycles. The analysis included 162 patients with a mean age of 7.23±3.73 years. Spastic tetraparesis was present in 46.9% of patients, spastic diplegia in 46.3%, and hemiplegic form in 6.8%. 3.1% of patients had GMFCS I, 19.1% had GMFCS II, 18.5% had GMFCS III, 44.4% had GMFCS IV, and 14.8% had GMFCS V. Initially, the severity of spasticity in the upper limbs was 2.33±0.71 points on the MAS, and spasticity in the lower limbs was 2.67±0.74 points on the MAS. The severity of sialorrhea on the DIS scale was 72.96±13.21 points. Results . All patients underwent one injection cycle (IC), of which 40.1% underwent two ICs, 19.1% underwent three ICs, and 12.3% underwent four ICs. The average dose for correction of spasticity of the upper limbs was 77.10±57.53 U, for NC – 157.10±68.59 U, for sialorrhea – 41.91±19.15 U, the average total dose of the drug per IC – 257.65±92.86 U (13.19±3.91 U/kg), maximum dose – 500 U. After the first IC, UL spasticity decreased by an average of 1.18 points on the MAS, and UL spasticity decreased by 1.23 points. The DIS sialorrhea score decreased by 27.3 points. Repeated ICs showed similar efficacy in correcting spasticity and sialorrhea. The overall improvement in sialorrhea on the GICS scale averaged 1.70±0.51 points after the first IC, and by the fourth IC it increased to 2.00±0.46 points, i.e., a tendency toward an increase in effect was noted. After the first IC, 8% of patients experienced AEs, most commonly pain at the injection site, less commonly dry mouth, increased saliva viscosity, and fever. The frequency of AEs did not increase with repeated ICs. Conclusion . Simultaneous treatment of spasticity and sialorrhea is a highly effective and safe approach in patients with CP. Repeated injections of incobotulinumtoxin A maintain the high efficacy and safety of this comprehensive therapeutic approach.

  • Multi-center open comparative randomized study of efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs Akatinol Memantine 10 mg (double-doses) in patients with vascular dementia

    by S.I. Gavrilova, I.V. Kolykhalov, N.M. Mikhaylova, E.V. Ponomareva, Ya.B. Fedorova, V.E. Medvedev, V.I. Frolova, E.V. Gushanskaya, I.V. Litvinenko, A.YU. Emelin, et al.

    OBJECTIVE Evaluation of the efficacy and safety of the drug Acatinol Memantine, 20 mg (once daily) in comparison with the drug Acatinol Memantine, 10 mg (twice daily) in patients with moderate to moderate severe vascular dementia. MATERIAL AND METHODS The study included 130 patients aged 50—85 years of both sexes with instrumentally and clinically confirmed vascular dementia. The patients were randomized into 2 groups. Group I consisted of 65 patients receiving Akatinol Memantine, 20 mg once daily, group II — 65 patients receiving Akatinol Memantine, 10 mg twice daily for 24 weeks. Clinical, parametric and statistical research methods were used. The Alzheimer’s disease assessment scale, the cognitive subscale (ADAS-cog), the short mental Status Assessment Scale (MMSE) and the general clinical impression scale for patients condition and illness severity (CGI-C and CGI-S) and the Hamilton Depression Rating scale (HAM-D) were used. Adverse events were collected and analyzed. RESULTS At week 24, both groups showed statistically significant positive change in ADAS-cog total score: in group I the total score was 27.2±8.76 points (absolute difference from baseline 3.5 points; pp<0.01) with no statistically significant differences between groups. Evaluation of secondary efficacy criteria (change in ADAS-cog total score at week 12 and MMSE at weeks 4, 12, and 24) also revealed statistically significant benefit in both groups compared to baseline with no significant differences between groups. Statistically significant improvement was noticed on CGI-S and CGI-C scales in both groups. Akatinol Memantine was safe and well tolerated in both groups. CONCLUSION The study showed no lesser efficacy and safety of Akatinol Memantine, 20 mg (once daily) compared to Akatinol Memantine, 10 mg (twice daily) in patients with moderate and moderately severe vascular dementia.